Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Thymus Neoplasms × Everolimus × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Breast Neoplasms 7 Neuroendocrine Tumors 5 Neoplasm Metastasis 4 Meningioma 3 Carcinoma, Renal Cell 3 Adenoma, Islet Cell 3 Glioma 2 Glioblastoma 2 Diffuse Intrinsic Pontine Glioma 2 Carcinoma, Hepatocellular 2 Carcinoid Tumor 2 Tuberous Sclerosis 1 Triple Negative Breast Neoplasms 1 Thymus Neoplasms 1 Sarcoma 1 Recurrence 1 Neoplasms 1 Metastatic Digestive System Neuroendocrine Tumor G1 1 Lymphangioleiomyomatosis 1 Locally Advanced Thyroid Gland Carcinoma 1 Kidney Neoplasms 1 HR+/HER2- Advanced Breast Cancer 1 Gastroenteropancreatic Neuroendocrine Tumors 1 Gastro-enteropancreatic neuroendocrine tumor 1 Gallbladder Neoplasms 1 Disease Progression 1 Colorectal Neoplasms 1 Brain Neoplasms 1 Astrocytoma 1 Advanced Lung Neuroendocrine Tumor 1

Interventions

fludarabine 1 Tumor Burden 1 Quality of Life 1 Proton Therapy 1 Immunotherapy 1 Histocompatibility Testing 1 Everolimus 1 Drug Therapy 1 Cyclophosphamide 1 Blood Specimen Collection 1 177Lu-octreotide, DOTA(0)-Tyr(3)- 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05918302 2026-03-06

LEVEL

Grupo Espanol de Tumores Neuroendocrinos

Phase 3 Recruiting

Thymus Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡